|  |
| --- |
| 10 April 2024  **Main press contact** **Janusz Berger**  Head of Market Communications  Health Care  Phone + 49 6151 18 4984  janusz.berger@evonik.com  Alternative press contact  Dr. Jürgen Krauter  Head of Market Communications Evonik Phone +49 6181 59-6847  [juergen.krauter@evonik.com](mailto:juergen.krauter@evonik.com) |
|  |

**Evonik Industries AG**

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

www.evonik.com

Supervisory Board  
Bernd Tönjes, Chairman  
Executive Board  
Christian Kullmann, Chairman  
Dr. Harald Schwager, Deputy Chairman  
Maike Schuh, Thomas Wessel

Registered Office is Essen

Register Court Essen Local Court

Commercial Registry B 19474

Evonik expands capacity for customized RESOMER® powder biomaterials

* New solvent-free micronization technology expanded at the Darmstadt site in Germany
* Manufacturing powders under ISO 13485 and GMP standards with customized particle sizes and broad range of material properties and degradation times
* Opening up new innovations in aesthetic applications and medical device manufacturing

**Darmstadt, Germany.** Evonik has expanded its capacities for RESOMER® powder biomaterials at its Darmstadt site in Germany. The specialty chemicals company now offers an advanced solvent-free micronization technology to produce custom powders with different particle sizes and material properties. With the new production capacities, Evonik also intends to expand its own portfolio of standard RESOMER® powders for medical devices to open up customized material solutions for precision implants or aesthetic applications.

Evonik’s new technology platform will open up opportunities to collaborate with customers to co-design and manufacture specialized RESOMER® powders with customized particle sizes for a broad range of medical applications. This systems-oriented approach to developing solutions with partners along the value chain is an important part of the 10-year vision adopted by Evonik’s life sciences division, Nutrition & Care, which inspires a customer-centric, systems-thinking mindset.

“Our micronization technology will empower customers to work with powders in the grade that they need - enabling them to further explore other aesthetic and medical treatments with our innovative biomaterials,” said Andreas Karau, global head of Medical Device Solutions at Evonik’s Health Care business line.

Evonik’s solvent-free micronization technology can be offered from small laboratory scale to commercial manufacturing. This allows customers to test and optimize their own formulations with smaller volumes of technical material before ordering larger commercial quantities that are manufactured under ISO 13485 and GMP standards.

Evonik is a leading global solutions provider of innovative materials for the medical device and pharmaceutical markets. Commercially available for more than 30 years, RESOMER® is Evonik's brand of bioresorbable polymers, renowned for its use in the production of resorbable medical devices and pharmaceuticals, with an established reputation for efficacy, biocompatibility, and safety. The RESOMER® powders provided by Evonik are of a quality suitable for implantable medical devices, adhering to stringent ISO 13485 and GMP compliance standards. The new micronization platform builds on Evonik’s extensive polymer design and processing expertise and experience in a wide range of applications.

**Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

**About Nutrition & Care**

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.